Pharsight

Intrarosa generic

Intrarosa is an intravaginal drug owned by Millicent and was authorized for market use on November 16, 2016. It contains the active ingredient prasterone and is available in vaginal insert dosage forms. Intrarosa holds a total of 3 patents, none of which have expired so far.

When will Intrarosa generic be available?

The generic version of Intrarosa could potentially be released after March 19, 2031. This release date is determined based on the expiry of Intrarosa's last patent. It's worth noting that the releasing of a generic drug is often subject to change due to various factors including but not limited to patent litigation and changes to the manufacturer's exclusivity period.

Intrarosa uses

Intrarosa utilizes its active ingredient, prasterone, to effectively treat dyspareunia. This symptom of vulvar and vaginal atrophy is often caused by menopause, and Intrarosa alleviates it with a daily dose of 6.5mg prasterone.

Intrarosa patent expiration

Intrarosa protects its formulation through a total of three patents. The last patent, holding the title 'Pharmaceutical compositions', is set to expire on March 19, 2031. When the last patent expires, it will open the door for the potential production of Intrarosa generic. Below are the details of the patent:

Intrarosa dosage

Want to ask something?